https://www.live-feeds.com/feed/lilly-s-dealmaking-spreads-the-wealth-among-a-broad-set-of-biotech-venture-investorsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/lilly-s-dealmaking-spreads-the-wealth-among-a-broad-set-of-biotech-venture-investorshttps://www.live-feeds.com/feed/lilly-s-dealmaking-spreads-the-wealth-among-a-broad-set-of-biotech-venture-investors#u55711Thu, 03 Sep 2026 13:15:34 +0000Eli Lilly is acquiring Merida Biosciences for up to $2.875 billion to advance treatments for serious allergic and autoimmune diseases. This purchase marks the company's 13th acquisition of 2026 and expands its presence in Massachusetts, where its local headcount now exceeds 1,400 employees. The deal reflects a broader strategy of dealmaking that distributes returns across a wide array of biotech venture investors. Merida Biosciences is described as a TED startup.Why it mattersLilly is aggressively expanding its portfolio through frequent acquisitions throughout 2026. This strategy focuses